Comparing the effects of the different antiangiogenic therapies and VEGF in xenotransplanted mice, our results revealed that bevacizumab was the only treatment that significantly decreased (p < 0.05) tumour growth in IPC-366 and SUM149 xenografts. The gene discussed is VEGFA; the disease is neoplasm.